nab-西罗莫司治疗恶性血管周上皮样细胞肿瘤
这项II期单臂注册试验评估了nab-西罗莫司治疗恶性PEComa的安全性和疗效。31例可评估患者的总缓解率为39%(95%CI 22-58),中位缓解持续时间未达到,中位无进展生存期10.6个月,中位总生存期40.8个月。TSC2突变患者缓解率显著更高(89% vs 13%,P<.001)。
要点
- nab-西罗莫司在恶性PEComa中总缓解率达39%,缓解快速且持久
- TSC2突变患者缓解率89%,显著高于无突变者的13%
- 中位无进展生存期10.6个月,中位总生存期40.8个月
核心结论
- nab-西罗莫司在恶性PEComa患者中具有活性,其缓解率、缓解持久性、疾病控制率和安全性支持其成为该病的重要新治疗选择。
研究设计与样本
- 患者接受nab-西罗莫司100 mg/m2静脉注射,每周一次连续2周,每3周为一周期。
- 主要终点为独立放射学评估的客观缓解率,关键次要终点包括缓解持续时间、无进展生存期和安全性。
主要发现
- 总缓解率为39%(12/31;95%CI 22-58),其中1例完全缓解,11例部分缓解。
- 52%(16/31)患者疾病稳定,10%(3/31)疾病进展。
- 缓解快速(67%在第6周时出现)且持久,中位缓解持续时间未达到(中位随访2.5年),12例缓解者中7例治疗仍在进行(范围5.6-47.2+个月)。
- 中位无进展生存期为10.6个月(95%CI 5.5个月-未达到),中位总生存期为40.8个月(95%CI 22.2个月-未达到)。
临床怎么用
- nab-西罗莫司可作为恶性PEComa患者的新治疗选择,尤其适用于TSC2突变患者。
局限性
- 单臂设计,样本量较小(31例可评估疗效),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570). PATIENTS AND METHODS: Patients with malignant PEComa were treated with nab-sirolimus 100 mg/m2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology review. Key secondary end points included duration of response, progression-free survival, and safety. A key exploratory end point was tumor biomarker analysis. RESULTS: Thirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a TSC2 mutation achieved a confirmed response versus 2 of 16 (13%) without TSC2 mutation (P < .001). The median progression-free survival was 10.6 months (95% CI, 5.5 months to not reached), and the median overall survival was 40.8 months (95% CI, 22.2 months to not reached). Most treatment-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade ≥ 4 treatment-related events occurred. CONCLUSION: nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.
引用
- Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021. PMID: 34637337. doi:10.1200/JCO.21.01728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。